Midatech Pharma PLC Change of Registered Office (9513I)

TIDMMTPH

RNS Number : 9513I

Midatech Pharma PLC

17 August 2021

17 August 2021

Midatech Pharma PLC

("Midatech" or the "Company")

Change of registered office

Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that its registered office address has changed, with immediate effect, to 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ.

For more information, please contact:

 
 Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: [phone] 
 www.midatechpharma.com 
 
 Panmure Gordon (UK) Limited (Nominated Adviser and Joint 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate Finance) 
 Rupert Dearden (Corporate Broking) 
 Tel: [phone] 
 
 Turner Pope Investments (TPI) Limited (Joint Broker) 
 Andrew Thacker / James Pope (Corporate Broking) 
  Tel: [phone] 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: [phone] 
 Email: [e-mail] 
 
 Edison Group (US Investor Relations) 
  Maxwell Colbert 
  Tel: [phone] 
  Email: [e-mail] 
 
 
 
             About Midatech Pharma PLC 
             Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
             MTP) is a drug delivery technology company focused on improving 
             the bio-delivery and bio-distribution of medicines. The Company 
             combines approved and development medications with its proprietary 
             and innovative drug delivery technologies to provide compelling 
             products that have the potential to powerfully impact the 
             lives of patients. 
             The Company has developed three in-house technology platforms, 
             each with its own unique mechanism to improve delivery of 
             medications to sites of disease. All of the Company's technologies 
             have successfully entered human use in the clinic, providing 
             important validation of the potential for each platform: 
              *    Q-Sphera(TM) platform: a disruptive micro-technology 
                   used for sustained release to prolong and control the 
                   release of therapeutics over an extended period of 
                   time (from weeks to months). 
 
 
              *    MidaSolve(TM) platform: an innovative nanotechnology 
                   used to dissolve insoluble drugs so that they can be 
                   administered in liquid form directly and locally into 
                   tumours. 
 
 
              *    MidaCore(TM) platform: a leading-edge nanotechnology 
                   used for targeting medications to sites of disease. 
 
 
 
             The platform nature of the technologies offers the potential 
             to develop multiple drug assets rather than being reliant 
             on a limited number of programmes. Midatech's technologies 
             are supported by 36 patent families including 120 granted 
             patents and an additional 70 patent applications. Midatech's 
             headquarters and R&D facility is in Cardiff, UK. For more 
             information please visit www.midatechpharma.com 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CROBLGDIGDBDGBR

(END) Dow Jones Newswires

August 17, 2021 12:23 ET (16:23 GMT)